

**Remarks**

Claims 15 and 16 are pending. Claim 17 has been canceled without prejudice to prosecution of this claim in a continuing application.

**§ 112 Rejections**

Claim 17 stands rejected under 35 USC § 112, second paragraph, allegedly as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention.

Claim 17 stands rejected under 35 USC § 112, first paragraph, allegedly for failing to comply with the written description requirement allegedly because the claimed method of inducing cytokine biosynthesis reaches out to activities/conditions/diseases mediated by a cytokine not yet identified.

Claim 17 stands rejected under 35 USC § 112, first paragraph, allegedly because the claim contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to use the invention.

Claim 17 has been cancelled without prejudice to prosecution of this claim in a continuing application. Accordingly, Applicant respectfully requests that these rejections be withdrawn.

**§ 101 Rejection**

Claim 17 stands rejected under 35 USC § 101, allegedly because recitation of the mechanism without the end result would have no utility. Claim 17 has been cancelled without prejudice to prosecution of this claim in a continuing application. Accordingly, Applicant respectfully requests that this rejection be withdrawn.

**§ 103 Rejections**

Claims 15-17 stand rejected under 35 USC § 103(a) as being unpatentable over U.S. Pat. No. 6,331,539 (Crooks) allegedly because one of ordinary skill in the art would be motivated to replace the butyl group at the 2-position with an ethyl group in Crooks' N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide.

This rejection is traversed. Reconsideration and removal of this rejection is respectfully requested.

The claimed compound, N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide possesses unexpectedly improved properties over Crooks' N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide (Crooks' compound). Using the "CYTOKINE INDUCTION IN HUMAN CELLS" assay described on pages 125-126 of the specification, the claimed compound and Crooks' compound were tested at the same time, at the same concentration, with the same reagents, including the same human PBMCs to determine the amounts of interferon  $\alpha$  (IFN- $\alpha$ ) and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) induced by each compound. The tests were carried out at a number of concentrations of the test compounds. These experiments were run multiple times.

Unexpectedly, the compound of the invention was found to induce much less TNF- $\alpha$  than that induced by Crooks' compound at all test concentrations. Amounts of TNF- $\alpha$  induced by each compound are shown in the following Tables 1-3.

Table 1

	Amount of TNF- $\alpha$ produced (pg/ml) at a 3.3 $\mu$ M concentration of test compound:	
Experiment No.	N-[4-(4-amino-2-ethyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide
3571	213	1808
3597	148	1827
3603	163	6812
3050	469	1674
3056	496	5080
3106	360	1030
4166	53	575

To summarize the results from Table 1,

at 3.3  $\mu$ M the average amount of TNF- $\alpha$  produced by N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide was 2686 pg/ml with a range of (575 to 6812 pg/ml),

while at 3.3  $\mu$ M the average amount of TNF- $\alpha$  produced by N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide was only 271 pg/ml with a range of (53-496 pg/ml)

Table 2

	Amount of TNF- $\alpha$ produced (pg/ml) at a 1.1 $\mu$ M concentration of test compound:	
Experiment No.	N-[4-(4-amino-2-ethyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide
3571	59	1641
3597	67	881
3603	143	3311
3050	106	2101
3056	84	6111
3106	91	836
4166	12	352

To summarize the results from Table 2,

at 1.1  $\mu$ M the average amount of TNF- $\alpha$  produced by N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide was 2176 pg/ml with a range of (352 to 6111 pg/ml)

while at 1.1  $\mu$ M the average amount of TNF- $\alpha$  produced by N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide was only 80 pg/ml with a range of (12-143 pg/ml)

Table 3

	Amount of TNF- $\alpha$ produced (pg/ml) at a 0.37 $\mu$ M concentration of test compound:	
Experiment No.	N-[4-(4-amino-2-ethyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide
3571	9	442
3597	28	363
3603	112	1029
3050	43	1068
3056	27	3343
3106	79	616
4166	4	110

To summarize the results from Table 3,

at 0.37  $\mu$ M the average amount of TNF- $\alpha$  produced by N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide was 996 pg/ml with a range of (110 to 3343 pg/ml),

while at 0.37  $\mu$ M the average amount of TNF- $\alpha$  produced by N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide was only 43 pg/ml with a range of (4-112 pg/ml)

This finding is of considerable significance. TNF- $\alpha$  is a pro-inflammatory cytokine, and although high levels of TNF- $\alpha$  are desirable for the treatment of some diseases, in many circumstances it can be undesirable such that lower levels are advantageous.

Furthermore, the compound of the invention was unexpectedly found to induce the production of significantly more IFN- $\alpha$  than that induced by Crooks' compound. This was found to be true over a range of concentrations, including 3.3, 1.1, and 0.37  $\mu$ M. The amounts of IFN- $\alpha$  induced by each compound are shown in the following Tables 4-6.

Table 4

	Amount of IFN- $\alpha$ produced (pg/ml) at a 3.3 $\mu$ M concentration of test compound:	
Experiment No.	N-[4-(4-amino-2-ethyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide
3571	3482	366
3597	6600	166
3603	1379	545
3050	595	627
3056	144	137
3106	2636	1572
4166	1052	1017

The results in Table 4 show that at the 3.3  $\mu$ M concentration N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide induced the production of significantly higher levels of IFN- $\alpha$  than that induced by N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide in 4 of 7 experiments. For these experiments a significant difference is defined as a greater than 50% difference in the amount of IFN- $\alpha$  produced.

Table 5

	Amount of IFN- $\alpha$ produced (pg/ml) at a 1.1 $\mu$ M concentration of test compound:	
Experiment No.	N-[4-(4-amino-2-ethyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide
3571	11210	333
3597	13545	182
3603	7968	604
3050	935	559
3056	418	133
3106	3315	1850
4166	2313	862

The results in Table 5 show that at the 1.1  $\mu$ M concentration N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide induced the production of significantly higher levels of IFN- $\alpha$  than that induced by N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide in 7 of 7 experiments. For these experiments a significant difference is defined as a greater than 50% difference in the amount of IFN- $\alpha$  produced.

Table 6

	Amount of IFN- $\alpha$ produced (pg/ml) at a 0.37 $\mu$ M concentration of test compound:	
Experiment No.	N-[4-(4-amino-2-ethyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i> ]quinolin-1-yl)butyl]methanesulfonamide
3571	8832	1167
3597	15759	1482
3603	6160	414
3050	1537	471
3056	607	94
3106	2463	2200
4166	2486	739

The results in Table 6 show that at the 0.37  $\mu$ M concentration N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide induced the production of significantly higher levels of IFN- $\alpha$  than that induced by N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide in 6 of 7 experiments. For these experiments a significant difference is defined as a greater than 50% difference in the amount of IFN- $\alpha$  produced.

In summary, the difference between the cytokine induction profiles of N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide and N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide described above is a useful and unexpected difference between the two compounds. In the concentration range of 3.3  $\mu$ M - 0.37  $\mu$ M, the compound of the invention induced higher levels of IFN- $\alpha$  production, but lower levels of TNF- $\alpha$  production than Crooks' compound. These important differences could not have been predicted based on the structures of these compounds.

The compound of the invention has been found to possess even further unexpected properties. The compound of the invention and the Crooks' compound were directly compared in an in vitro assay designed to determine the potential of a compound to produce changes in cardiac rhythm. In this test the concentration of compound required to inhibit 50% of HERG potassium channels (IC<sub>50</sub>) was determined. The HERG potassium channel inhibition assay is used as a model to predict the potential of a compound to prolong the repolarization of cardiac cells (i.e. QT interval). Drug-induced QT interval prolongation is associated with sudden cardiac death.

The assay was run as follows. Human ERG (HERG) -transfected Chinese Hamster Ovary (CHO) cells were plated into a 96-well microplate and incubated overnight. Cells were loaded with RbCl (5.4 mM) and incubated at 37°C for 1 hr. Excess RbCl was removed by washing three times with KCl buffer (5.4 mM). The test compound and test inhibitor (E-4031) were added separately at various concentration levels and the cells further incubated at 37°C for 10 min. The HERG channels were activated by adding elevated extracellular K<sup>+</sup> (60 mM). The supernatant (SN) was removed and collected, while the cell pellet was resuspended with lysis buffer (1% (v/v) Triton X-100). Rb<sup>+</sup> concentrations in cell supernatant and cell lysate fractions were quantitated by atomic absorption spectroscopy (Ion Channel Reader (ICR) 8000 (Aurora Biomed Inc., Vancouver, B.C.)). Rb<sup>+</sup> efflux rate was calculated using:  $[Rb^+]_{SN}/[Rb^+]_{Total}$ . This is the IC<sub>50</sub> value. Because this is an assay to measure the interaction of test compound with potassium channels, the higher the IC<sub>50</sub> value, the less chance there is for an undesired cardiac rhythm change. The results from the assay were as follows:

compound of the invention: HERG IC<sub>50</sub> = 29 μM

Crooks' compound: HERG IC<sub>50</sub> = 7.7 μM

Thus, the compound of the invention is distinguished from the Crooks' compound based on interaction with potassium channels.

The compound of the invention and the Crooks' compound were also directly compared with regard to metabolic stability (i.e. resistance to compound modification in the liver). In an in vitro assay, a set amount of test compound was exposed to a set amount of human liver microsomes, and the time required for half of the test compound to be metabolized (t<sub>1/2</sub>) was determined.

The assay was carried out as follows. Human liver microsomes (pooled from multiple human livers) were incubated at 37 °C in the presence of 1 µM test compound and an NADPH-regenerating system. Samples are quenched at 0, 10, and 60 minutes. Amount of test compound (peak area) remaining relative to 0 minute was determined by LC/MS/MS. Peak areas were natural log transformed and plotted vs. time. The rate of compound disappearance was determined by linear regression and the half-life ( $t_{1/2}$ ) calculated from rate. The results were as follows:

compound of the invention:  $t_{1/2} = > 240$  minutes

Crooks' compound:  $t_{1/2} = 100$  minutes

A compound with a longer  $t_{1/2}$  is more slowly metabolized and is a better candidate for oral dosing. That is, a longer  $t_{1/2}$  indicates that the compound is less likely to be removed prior to entering systemic circulation by the "first-pass effect" and has greater metabolic stability. Thus, the compound of the invention possesses much greater metabolic stability than Crooks' compound.

These findings clearly show that the claimed compound possesses unexpectedly improved properties over those of Crooks' compound. Accordingly, the compound of claim 15, the pharmaceutical composition of claim 16 comprising the compound of claim 15, and the method of claim 17 using the compound of claim 15 are unobvious over U.S. Pat. No. 6,331,539.

Applicants, therefore, respectfully submit that the 35 U.S.C. § 103(a) rejection of claims 15, 16, and 17 has been overcome, and respectfully request that this rejection be withdrawn.

### **Obviousness-Type Double Patenting**

Claims 15-17 are rejected under the judicially created doctrine of obviousness-type double patenting as being allegedly unpatentable over claims 1-31 of U.S. Patent No. 6,331,539 for the reasons set forth in the 35 U.S.C. § 103(a) rejection of claims 15-17. For the reasons given in traversing the 35 U.S.C. § 103(a) rejection, Applicants respectfully request that this rejection be withdrawn.

Claim 17 is provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being allegedly unpatentable over claims 29, 32, 35, and 38-43 of copending Application No. 10/027272 for the reasons set forth in the 35 U.S.C. § 103(a) rejection of claims



15-17. For the reasons given in traversing the 35 U.S.C. § 103(a) rejection, Applicants respectfully request that this rejection be withdrawn.

Claims 15 and 16 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being allegedly unpatentable over claims 33 of copending Application No. 10/166,321 for the reasons set forth in the 35 U.S.C. § 103(a) rejection of claims 15-17. For the reasons given in traversing the 35 U.S.C. § 103(a) rejection, Applicants respectfully request that this rejection be withdrawn.

In view of the above, it is submitted that the application is in condition for allowance. Reconsideration of the application is requested.

Allowance of claims 15 and 16, at an early date is solicited.

Respectfully submitted,

19 July 2004  
Date

By: Dean A. Ersfeld  
Dean A. Ersfeld, Reg. No.: 46,689  
Telephone No.: (651) 733-7830

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: 651-736-3833